Navigation Links
Unilife Corporation Announces Financial Results for Fiscal Year 2011 First Quarter
Date:11/15/2010

LEWISBERRY, Pa., Nov. 15, 2010 /PRNewswire-FirstCall/ -- Unilife Corporation ("Unilife" or "Company") (Nasdaq: UNIS; ASX: UNS) today announced financial results for the three months ended September 30, 2010 (Fiscal Year 2011 First Quarter).

Recent Company Highlights:

  • Construction of new global headquarters and production facility in York, PA remains fully on schedule for completion in late-2010. Expected staff relocation during mid-December 2010
  • Transfer and installation of Unitract® and Unifill® automated assembly lines into York facility scheduled to occur between late-December 2010 and early 2011
  • Secured $18 million mortgage from Metro Bank in October 2010 to support the York facility U.S. Department of Agriculture (USDA) agreed to guarantee $10 million of the loan
  • Commences Unitract 1mL syringe sales in the U.S. with appointment of IMCO, a national co-operative of independent medical device distributors. Receives 510K FDA clearance for Unitract 1mL Tuberculin syringe

  • Mr. Alan Shortall, Chief Executive Officer of Unilife, stated, "During the first fiscal quarter of 2011, our business focus has continued to be directed towards building our operational capabilities to meet projected demand from pharmaceutical and healthcare companies for our proprietary products. We are pleased to advise that as a result of these efforts, this phase of significant investment in our operational infrastructure is now nearing completion. In particular, we have made excellent progress this quarter towards the completion of our new, state-of-the-art facility in York, PA and the industrialization program for the Unifill syringe. We remain on schedule to move into the new facility next month, with commercial production of the Unifill syringe scheduled to commence during the third fiscal quarter of 2011.

    "Preparations for the commercial supply of the Unifill syringe to pharmaceutical customers are well underway.  Discussions with many interested pharmaceutical companies continue to accelerate in parallel across several therapeutic markets, with Unilife also receiving prominent industry attention during recent pharmaceutical events.

    "We are also pleased to have secured an $18 million mortgage with Metro Bank of Harrisburg for the construction of our new facility in York, PA. We are especially grateful for the strong government backing we have received for this project, with the Federal Government underwriting $10 million of the mortgage and the Commonwealth of Pennsylvania also making significant contributions towards our facility's construction.

    "In addition, Unilife is delighted to announce the commencement of U.S. sales and shipments for its Unitract range of 1mL syringes, with the signing of an agreement with Independent Medical Co-Op, Inc. ("IMCO"), one of the nation's largest co-operatives of independent medical device distributors.  IMCO is ideally positioned to act as a preferred, non-exclusive partner to support our launch activities, given their specialist focus and market reach within those healthcare sectors where the use of 1mL safety syringes is greatest. We look forward to working with IMCO and their members to successfully introduce our Unitract 1mL syringes to U.S. healthcare facilities," Mr. Shortall said.

    Financial Results for Three Months Ended September 30, 2010Revenues for the three months ended September 30, 2010 were $3.5 million compared to $3.1 million for the same period in 2009.

    The Company's net loss for the three months ended September 30, 2010 was $7.2 million, or $0.14 per diluted share, compared to net loss of $2.1 million, or $0.06 per diluted share, for the same period in 2009. The increase in the net loss was attributable to higher payroll and related expenses due to increases in the workforce at the Lewisberry, PA facility, higher share-based compensation expense, and increased research and development expenses to finalize the product specifications of our Unifill syringe.

    Adjusted net loss for the three months ended September 30, 2010, which excludes approximately $3.4 million in share-based compensation expense, depreciation and amortization and interest expense was $3.9 million, or $0.07 per diluted share, compared to adjusted net loss of $0.7 million, or $0.02 per diluted share, for the same period in 2009.  

    As of September 30, 2010, the Company's cash, cash equivalents and restricted cash were $16.0 million, which included $7.0 million of restricted cash used to secure our bridge financing for our new building.  

    Conference Call InformationManagement has scheduled a conference call for 4:30 p.m. U.S. Eastern Standard Time on November 15, 2010, to review the Company's financial results, market trends and future outlook.  The conference call and accompanying slide presentation will be broadcast over the Internet as a "live" listen only Webcast.  An archive of the presentation and webcast will be available for 30 days after the call.  To listen, please go to: http://ir.unilife.com/events.cfm.

    About Unilife CorporationUnilife Corporation is a U.S.-based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic, operator-controlled needle retraction features which are fully integrated within the barrel, and are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife is ISO 13485-certified and has FDA-registered medical device manufacturing facilities in Pennsylvania.

    This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.  

    Non-GAAP Financial MeasuresU.S. securities laws require that when we publish any non-GAAP financial measure, we disclose the reason for using the non-GAAP measure and provide a reconciliation to the most directly comparable GAAP measure.  The presentation of adjusted net income (loss) and adjusted net income (loss) per share are non-GAAP measures.  Adjusted net income (loss) represents net income (loss) calculated in accordance with U.S. GAAP as adjusted for the impact of share-based compensation expense, depreciation and amortization, interest expense and certain non-recurring costs associated with our redomiciliation and Nasdaq listing.

    Management believes the presentation of adjusted net income (loss) and adjusted net income (loss) per share provides useful information because these measures enhance its own evaluation, as well as investor's understanding, of the Company's core operating and financial results.  Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results.  A reconciliation of net income (loss) to adjusted net income (loss) is included in the attached table.

    General: UNIS-G Investor Contacts (US):Investor Contacts (Australia)Todd Fromer / Garth Russell

    Stuart Fine

    Jeff CarterKCSA Strategic Communications

    Carpe DM Inc

    Unilife CorporationP: + 1 212-682-6300

    P: + 1 908 469 1788

    P: + 61 2 8346 6500(Tables Below)UNILIFE CORPORATION AND SUBSIDIARIESConsolidated Balance Sheets(in thousands, except share data) (unaudited)September 30,
    2010June 30,
    2010AssetsCurrent Assets:Cash and cash equivalents

    $
    8,990

    $
    20,750Restricted cash

    7,000

    —Accounts receivable

    2,168

    1,556Inventories

    1,122

    797Prepaid expenses and other current assets

    680

    637Total current assets

    19,960

    23,740Property, plant and equipment, net

    36,045

    29,972Goodwill

    12,173

    10,792Intangible assets, net

    43

    40Other assets

    285

    273Total assets

    $
    8,506

    $
    4,817Liabilities and Stockholders’ EquityCurrent Liabilities:Accounts payable

    $
    4,193

    $
    ,044Accrued expenses

    3,228

    2,911Note payable

    6,900

    —Current portion of long-term debt

    1,628

    1,648Deferred revenue

    2,477

    2,188Total current liabilities

    18,426

    12,791Long-term debt, less current portion

    1,053

    1,093Deferred revenue

    6,812

    6,563Total liabilities

    26,291

    20,447Stockholders Equity:Preferred stock, $0.01 par value, 50,000,000 shares authorized as of September 30, 2010; none issued or outstanding as of September 30, 2010 and June 30, 2010

    —Common stock, $0.01 par value, 250,000,000 shares authorized as of September 30, 2010; 55,480,455 and 54,761,848 shares issued and outstanding as of September 30, 2010 and June 30, 2010, respectively

    555

    548Additional paid-in-capital

    126,064

    122,397Accumulated deficit

    (86,896)

    (79,650)Accumulated other comprehensive income

    2,492

    1,075Total stockholders equity

    42,215

    44,370Total liabilities and stockholders equity

    $
    8,506

    $
    4,817UNILIFE CORPORATION AND SUBSIDIARIESConsolidated Statements of Operations(in thousands, except per share data)(unaudited)Three Months EndedSeptember 30,20102009RevenuesIndustrialization fees

    $
    ,350

    $
    ,745Licensing fees

    577

    683Product sales and other

    1,616

    680Total revenues

    3,543

    3,108Cost of product sales

    1,175

    829Gross profit

    2,368

    2,279Operating expenses:Research and development

    1,005

    399Selling, general and administrative

    8,012

    3,742Depreciation and amortization

    787

    291Total operating expenses

    9,804

    4,432Operating loss

    (7,436)

    (2,153)Interest expense

    32

    47Interest income

    (122)

    (5)Other income

    (100)

    (131)Net loss

    $
    (7,246)

    $
    (2,064)Loss per share:Basic loss per share

    $
    (0.14)

    $
    (0.06)Diluted loss per share

    $
    (0.14)

    $
    (0.06)UNILIFE CORPORATION AND SUBSIDIARIESReconciliation of Non-GAAP Measure(in thousands, except per share data)(unaudited)Three Months EndedSeptember 30,20102009Net loss

    $
    (7,246)

    $
    (2,064)Share-based compensation expense

    2,550

    570Depreciation and amortization

    787

    291Interest expense

    32

    47Non-recurring costs associated with redomiciliation & US listing*

    -

    457Adjusted net loss

    $
    (3,877)

    $
    (699)Adjusted net loss per share –diluted

    $
    (0.07)

    $
    ( 0.02 )* Includes legal, consulting and other professional fees incurred in connection with the Company's redomiciliation to the United States and Nasdaq listing.
    '/>"/>

    SOURCE Unilife Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Unilife Commences U.S. Sales of Unitract® 1mL Syringes
    2. Unilife Corporation Schedules Fiscal 2011 First Quarter Conference Call For Monday, November 15, 2010
    3. Unilife Secures U.S. Government Financial Backing for the Completion of New Global Headquarters and Manufacturing Facility in York, PA
    4. Unilife Corporation Secures FDA 510k Clearance for the Unitractâ„¢ 1mL Tuberculin Syringe
    5. Unilife Corporation Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2010
    6. Unilife Corporation Schedules Fiscal 2010 Fourth Quarter and Year End Conference Call for Monday, August 30, 2010
    7. Unilife Corporation Commences Trading on the NASDAQ Global Market Under the Ticker Symbol UNIS
    8. China Cord Blood Corporation Commences Warrant Exchange Offer
    9. Luminex Corporation to Present at Stephens Fall Investment Conference
    10. Microfluidics International Corporation to Report Third Quarter 2010 Financial Results on November 16, 2010
    11. Amarin Corporation to Host Investor Conference Call on Wednesday, November 10, 2010
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/28/2016)... NEW YORK , April 28, 2016 /PRNewswire/ ... will notably complement the company,s valve repair and ... the move also places Abbott more firmly into ... one of the fastest growing device areas, with ... to its recent report,  Advanced Remote Patient ...
    (Date:4/28/2016)... , April 28, 2016  Marking its one ... breast and ovarian cancer risk test, Color ... 30 genes that highly impact the most common ... today, the Color Test analyzes hereditary cancer risks ... and uterine cancers. The Color Test is physician ...
    (Date:4/28/2016)... NEW YORK , April 28, 2016  The ... reached 275 million dollars, according to Kalorama Information and ... includes typing, immunoassays and nucleic acid testing.  The healthcare ... had made progress in developing blood collection stations and ... was made in Kalorama Information,s report, Blood ...
    Breaking Medicine Technology:
    (Date:4/30/2016)... ... April 30, 2016 , ... Powerful ... with Hypnotherapist, Mary O'Maley. What is hypnosis and hypnotherapy and why after ... weight control), pain relief (chronic and acute), birthing processes and medical procedures, depression, ...
    (Date:4/30/2016)... ... April 30, 2016 , ... ... 2016 questioned the use of the HyProCure sinus tarsi implant. ( http://www.cbc.ca/news/canada/ottawa/banned-quebec-dentist-pierre-dupont-working-as-chiropodist-in-ottawa-1.3515494 ... EOTTS-HyProCure is a minimally invasive procedure performed, when indicated, to correct the ...
    (Date:4/29/2016)... Ferry, New York (PRWEB) , ... April 30, 2016 , ... ... the Dobbs Ferry campus. The following programs will be expanding due to high ... Management (HRM). The expansion will begin this summer. , School of ...
    (Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic ... the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula for brain ... mood optimization products to the store is just one more way Shamangelic Healing ...
    (Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... ... advocating optimistic healthcare awareness and author of best seller "LOVE, MEDICINE and MIRACLES") ... Radio Monday, May 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, ...
    Breaking Medicine News(10 mins):